
The FDA approves Wilserdly on Monday, November 16, 2026, giving patients with a hard-to-treat form of advanced breast cancer the first oral drug built to attack the mutation behind hormone resistance. The approval covers Roche's giredestrant, a once-daily 30 mg tablet taken with everolimus, for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has returned or progressed after endocrine treatment.
The decision rests on the phase III evERA trial, published in The New England Journal of Medicine. In 207 patients with ESR1-mutated tumours, the combination cut the risk of progression or death by 62 percent against standard endocrine therapy plus everolimus, holding the cancer at bay for a median of 10 months versus 5.5 months. Roche priced it at $22,500 a month, with US availability in the coming weeks.
Roche announced the approval on Monday, November 16, 2026, after the FDA cleared Wilserdly with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, confirmed by an FDA-authorised test, whose disease recurred during or after endocrine-based adjuvant therapy or progressed on at least one endocrine-based regimen.
The approval makes Wilserdly the first next-generation oral SERD to reach patients in this setting. Until now, the only drug in the class that degrades the oestrogen receptor, fulvestrant, has been given by injection in a clinic. Wilserdly is a tablet taken at home, once a day, paired with everolimus, which blocks a second growth pathway.
Most breast cancers are driven by oestrogen. About 70 percent of cases are hormone receptor-positive and HER2-negative, so their cells use oestrogen to grow. Endocrine therapy, which starves the tumour of oestrogen or blocks the receptor, is the backbone of treatment, but over time the cancer often learns to escape, and the ESR1 mutation is the main reason why.
ESR1 mutations change the shape of the oestrogen receptor so it stays switched on even with no oestrogen present. Roche says up to 40 percent of patients with hormone receptor-positive metastatic breast cancer develop these mutations, the main cause of hormone therapy resistance. Once the mutation appears, standard endocrine drugs lose much of their power.
That is the gap Wilserdly fills. As a selective oestrogen receptor degrader, it blocks oestrogen from binding to the receptor and triggers the breakdown of the receptor protein itself. Its effect is strengthened with an mTOR inhibitor such as everolimus, which attacks a second resistance pathway at the same time. Read our earlier report on babies born with measles in the US for the first time in decades.
In the 207 patients with ESR1-mutated tumours, Wilserdly plus everolimus reduced the risk of disease progression or death by 62 percent compared with standard endocrine therapy plus everolimus, a stratified hazard ratio of 0.38, with a 95 percent confidence interval of 0.27 to 0.54 and a p-value below 0.0001. Median progression-free survival reached 10 months on the new combination, against 5.5 months on standard treatment.
It is the first time an all-oral SERD combination has beaten standard endocrine combination head-to-head in a phase III trial after CDK4/6 inhibitor treatment. Eligibility depends on a blood test authorised by the FDA, which detects the ESR1 mutation.
Roche chief medical officer Dr Levi Garraway said resistance to endocrine therapy remains a substantial challenge for these patients. "By pairing potent oestrogen receptor degradation with everolimus, Wilserdly offers a targeted, all-oral regimen that significantly delays disease progression and allows advanced breast cancer patients to take their treatment from home," he said.
Dr Erica L. Mayer, of the Dana-Farber Cancer Institute, said patients whose cancer progresses on endocrine therapy face difficult choices as options narrow. "The evERA trial demonstrates that the oral giredestrant combination regimen directly targets the primary genomic drivers of resistance, offering patients prolonged disease control through a fully oral therapeutic option," she said.
Roche Pharmaceuticals chief executive Teresa Graham called it a pivotal step against aggressive, treatment-resistant breast cancer. "For more than three decades, Roche has transformed care across oncology, and this first approval for Wilserdly marks a pivotal leap forward in addressing aggressive, treatment-resistant breast cancer," she said.
The approval matters first for patients who have run out of easy answers. For a woman whose cancer has spread and whose tumour carries an ESR1 mutation, the standard hormone drugs have often stopped working, and the next steps have meant injections or chemotherapy. An oral tablet taken at home changes the daily reality of treatment.
At $22,500 a month, access will depend on insurance coverage and Roche's patient support programmes. Read our report on singer Nicole Taylor, who died at 35 after a breast cancer battle.
The next milestone comes quickly. The FDA is reviewing Wilserdly as an adjuvant treatment, given after surgery, with a decision expected by November 30, 2026. If approved, it would be the first SERD cleared for both adjuvant and advanced ER-positive breast cancer, and the first new adjuvant endocrine therapy in more than 20 years.
Roche is also running six phase III trials of Wilserdly, with filings under way outside the United States. For patients, the immediate question is access: who will be tested for the ESR1 mutation, and how quickly insurers will cover a $22,500-a-month tablet.
What is Wilserdly?
Wilserdly is the brand name for giredestrant, a next-generation oral selective oestrogen receptor degrader (SERD) made by Roche. It blocks oestrogen from binding to its receptor and triggers the receptor's breakdown, slowing hormone-driven breast cancer.
Who can receive Wilserdly?
Adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, confirmed by an FDA-authorised test, whose disease recurred during or after endocrine-based adjuvant therapy or progressed on at least one endocrine-based regimen, taken with everolimus at 30 mg once daily.
How well does Wilserdly work?
In the phase III evERA trial of 207 ESR1-mutated patients, Wilserdly plus everolimus cut the risk of progression or death by 62 percent versus standard endocrine therapy plus everolimus; median progression-free survival was 10 months against 5.5 months.
How much does Wilserdly cost?
Roche priced it at $22,500 per month, with US availability expected in the coming weeks and access depending on insurance coverage.
What happens next for Wilserdly?
The FDA is reviewing Wilserdly as an adjuvant treatment after surgery, with a decision expected by November 30, 2026.